SCHEMBL5163015

SCHEMBL5163015

CCNc1nc(SCCCc2ccccc2)nc2c1nc(-c1ccco1)n2-c1ccc(OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.45
ADORA1 P30542 6/20 0.45
TMIGD3 P0DMS9 5/20 0.45
ADORA2B P29275 5/20 0.45
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 5/20 0.41
HSD17B10 Q99714 4/20 0.41
HPGD P15428 4/20 0.41
CASP1 P29466 3/20 0.41
CASP7 P55210 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
APAF1 O14727 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5351461 0.96 ADORA1 (0.44) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5163808 0.93 ADORA1 (0.47) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5178357 0.88 ADORA1 (0.47) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5158815 0.85 ADORA1 (0.48) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5362027 0.85 ADORA2A (0.53) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5161088 0.84 ALDH1A1 (0.42) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5163082 0.84 ADORA2A (0.52) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5359337 0.83 ADORA2A (0.46) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5159207 0.80 ALDH1A1 (0.44) ADORA2AADORA1TMIGD3ADORA2BALDH1A1
SCHEMBL5158790 0.78 ADORA1 (0.50) ADORA2AADORA1TMIGD3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
EP-1456209-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-09-15 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed
WO-2003051882-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ADORA2A 1/4885ADORA1 4/4885TMIGD3 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.